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OBJECTIVES: Liver function tests (LFTs) are routinely
requested in primary care often leading to further invasive and
expensive investigations. In patients with raised LFTs without
clinically apparent liver disease the appropriate level of follow-up
can be unclear. The aim was to determine the most cost-effective
GP strategy. METHODS: A retrospective population-based
observational study followed-up all Tayside patients who had
incident LFTs in primary care, with no clinically obvious liver
disease (n = 95,977), to subsequent liver disease diagnosis. Pre-
diction models allowed identiﬁcation of patients at high risk of
liver disease. A decision tree modelled the patient journey from
two main GP decisions—retest or refer to secondary care. Tran-
sition probabilities of retests, referral and liver disease diagnosis
were calculated from biochemistry and liver databases. The
outcome was liver disease diagnosed within one year. Patients
having further investigations carried out at referral were identi-
ﬁed from virology, immunology and pathology datasets. Costs of
investigations in primary and secondary care were obtained from
various sources. Utilities were obtained from systematic review,
and patient survey at the liver clinic at Ninewell’s Hospital,
Dundee. The incremental cost-utility ratio (ICUR) was calcu-
lated. Sensitivity analysis was performed for all parameters.
RESULTS: For the average patient with abnormal LFTs the
retesting strategy dominated referral. However, for patients in
the top percentile of liver disease risk, referral to secondary care
was more cost-effective (ICUR = £7588/year). The average cost
of referral was £11.20 lower per patient than retesting. Retesting
QALY gain was only 0.001. Sensitivity results varied although
referral was in the main more cost-effective. CONCLUSIONS:
This is the ﬁrst cost-utility analysis of GP strategies for patients
with abnormal LFTs. It is more cost-effective to refer patients
with abnormal LFTs who have high risk of liver disease identiﬁed
by the model, whilst those with average risk should be retested in
primary care.
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OBJECTIVES: This study estimates the cost and the effectiveness
of terlipressin and somatostatin in the treatment of bleeding
oesophageal varices (BOV) in Spain. METHODS: A Markov
model was created with the following ﬁve states: patient with
cirrhosis, bleeding, re-bleeding, endoscopy treatment, transjugu-
lar intrahepatic portosystemic shunt, and death. Efﬁcacy data on
survival, re-bleeding and control of bleeding were obtained from
high quality studies reported in Cochrane meta-analyses. Base-
line outcomes related to the course of disease and health-state
utilities were derived from published sources. Treatment costs
and all related BOV costs were obtained from a panel of experts
and published Spanish sources. RESULTS: The average aggre-
gated treatment cost per person for all medical interventions at
5 years was lower for terlipressin-treated patients (€5165)
compared with those treated using somatostatin (€5439). Costs
considered in the study were pharmacologic treatment costs,
laboratory and diagnostic tests costs, specialist consultation costs
and hospitalization costs. All costs are referred to year 2008. The
incremental analysis comparing terlipressin with somatostatin
using a cost per quality adjusted life year (QALY) approach
indicated that terlipressin was the dominant BOV treatment
option (i.e. it cost less and it was more effective). CONCLU-
SIONS: Results from base-case and sensitivity analysis indicate
that terlipressin is a cost-effective treatment for BEV when it is
compared to somatostatin in the Spanish setting.
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OBJECTIVES: To describe the relationship between increasing
intensity of symptoms and reduced work productivity in GERD
patients and effects on cost in a real life primary care setting in
Spain. METHODS: In this retrospective, observational study,
a random sample of all patients visiting a primary health care
center for any reason related to GERD over a 4-month period
were included. Patients were invited to participate, and those
who accepted attended an interview during which clinical data
were collected. Information regarding work productivity was
collected using the Work Productivity and Activity Impairment
questionnaire GERD (WPAI-GERD) and symptoms using the
Reﬂux Disease Questionnaire (RDQ). Both use a 7-day recall
period and are validated questionnaires. RESULTS: Overall,
63,416 patients were identiﬁed during the study period. In 1727
(2.7%) patients GERD was a reason for the visit. Of these, 579
patients were randomly selected and 87% participated in the
study; Mean age was 60 years (SD: 15,7), 59% were women. On
average, patients were absent from work 2.9 hours per week, and
mean work time lost due to reduced productivity was 7.7 hours
per week. The mean monetary value of these productivity losses
was €117.6€ per patient. There was an increase in cost of reduced
productivity as the RDQ score increased: R2: 0.26, 0.23, 0.29
and 0.28 for heartburn, acid regurgitation, GERD and dyspepsia
dimensions, respectively. When patients with high symptom load,
according to frequency and intensity, were studied separately,
coefﬁcients increased to 0.34, 0.34, 0.42 and 0.36, respectively.
The monetary value of productivity losses increased from €3.8€
to €31.0€ and to €132.7€ when heartburn intensity increased
from mild to moderate and to severe, respectively. Likewise,
when acid regurgitation was considered, the increase was from
€7.7€ to 32.47 and to €175.18. CONCLUSIONS: GERD has a
mayor impact on patients’ productivity. Increasing intensity of
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OBJECTIVES: To develop the Bowel Cleansing Impact Review
(BOCLIR), a new questionnaire designed to assess patient
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response to bowel cleansing products, and to assess the psycho-
metric and scaling properties of the new measure. METHODS:
Instrument content was derived via qualitative interviews con-
ducted with patients in the UK. Face and content validity were
assessed via patient cognitive-debrieﬁng interviews. Psychometric
and scaling properties were assessed via a survey. Patients com-
pleted the BOCLIR and demographic questions prior to colonos-
copy. Item response theory (Rasch analysis) was employed for
item reduction and unidimensionality. Internal consistency and
construct validity (association of BOCLIR scores with known
factors) were also assessed. RESULTS: Qualitative interviews
(n = 40/58%M) highlighted key areas of patient concern as;
satisfaction with the bowel cleanser, impairments (adverse
events) and activity limitations. A draft questionnaire was con-
structed comprising three scales addressing these areas.
Cognitive-debrieﬁng interviews (n = 19/63%M) demonstrated
BOCLIR’s acceptability, relevance, clarity and ease of comple-
tion. Survey sample: n = 166/52%M, mean age 54.3/SD 15.2
years. Application of Rasch analysis removed misﬁtting or redun-
dant items. Final scales ﬁt the Rasch model as indicated by
non-signiﬁcant c2 p-values (p > 0.13 for all scales), conﬁrming
unidimensionality. Cronbach’s alpha coefﬁcients were high indi-
cating good internal consistency; Satisfaction 0.84, Impairments
0.77, Activities 0.94. There were signiﬁcant differences in
BOCLIR scores between patients based on their willingness to
use the product in future and on ease of drinking the full prepa-
ration (p < 0.01). For Impairments and Activities scales signiﬁ-
cant differences were also observed between patients dependent
on how well they felt and satisfaction with the preparation
(p < 0.001). CONCLUSIONS: The BOCLIR is a new question-
naire comprised of unidimensional scales (satisfaction, impair-
ments and activities) with good psychometric and scaling
properties. The BOCLIR will allow accurate assessment of
patients’ response to bowel cleansing preparations.
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OBJECTIVES: Ulcerative colitis (UC) is a chronic inﬂammatory
condition characterised by remission and relapse. Although UC
disease severity is a strong predictor of quality of life, the impact
of disease relapse on health-related utility compared to remission
has never been characterised. It has been found that at 12
months, 71% of subjects remained in remission on once daily
mesalazine (Pentasa; 1x2g) vs. 59% in twice-daily mesalazine
(2x1g), p = 0.024, using Kaplan Meier analysis (Dignass, 2007).
METHODS: The purpose of this study was to examine quality of
life by estimating changes in health-related utility associated with
transition from a remitting to relapsing states in adults with
established UC. Data were analysed from the Phase-3 PODIUM
trial (Pentasa Once Daily In Ulcerative colitis for Maintenance of
remission). Patients were classiﬁed into the following disease
states at baseline and at 12 months based on their UC disease
activity index (UC-DAI): remission, 2; mild/moderate relapse,
3–8; and severe relapse, 9. Health utility was estimated by
Monte Carlo bootstrap simulation using a response mapping
algorithm to predict EQ-5D domain response from UC-DAI item
scores and applying the UK tariff for preference based utility.
RESULTS: Evaluable data were available for 359 patients, 53%
of whom were male, with a mean age at screening of 48 years (SD
 15). At baseline, all patients were in remission and had a mean
EQ-5D index of 0.945 (SD  0.023). At 12 months, 73.8% of
patients remained in remission, 22.6% were in mild/moderate
relapse, and 3.6% were in severe relapse. There were no baseline
differences between patients relapsing or remitting at 12 months;
however, signiﬁcant differences in utility emerged at 12 months.
For patients in remission at 12-months, their mean utility was
0.940 units (95%CI 0.937–0.943), whilst for mild/moderate
relapsing cases their mean utility was 0.775 units (95%CI 0.751–
0.800) and 0.660 units (95%CI 0.595–0.725) for those in severe
relapse (p < 0.001). CONCLUSIONS: Patients with relapsing
UC showed considerable decrease in health-related utility con-
sistent with disease severity. Patients in mild/moderate relapse
had health-related utility comparable to those with cardiac dys-
rhythmia (0.774) or gout (0.771), whilst severe relapsing patients
had similar disutility to those with emphysema (0.663) or renal
failure (0.651). Maintenance treatments that prolong the UC
remission phase are likely to have substantial beneﬁts on health
related utility.
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OBJECTIVES: Additional validity evidences have been gathered
to support the adequacy of the Gastrointestinal Short Form
Questionnaire (GSFQ) adapted to (Iberian) Spanish culture. The
GSFQ questionnaire is a speciﬁc HRQoL instrument which
measures the impact of Gastroesophageal Reﬂux Disease (GERD)
symptoms. If the GSFQ is to be a valid measure of patient’s
HRQoL it should be possible to stratify and discriminate patients
using the questionnaire score as criteria. METHODS: A national
representative sample of GERD patients was selected, stratiﬁed by
gender, age (<45, 45 years) and GERD severity (0-I, II-IV
Savary-Miller score) for validation purposes. Age, gender, BMI,
GERD diagnose, GERD severity, associated comorbidities and
risk factors were recorded. GSFQ, EuroQol, and the correspond-
ing Visual Analogue Scale (VAS) were answered by patients. A
semantic reduction of reported comorbidities was carried out to
attain a ﬁnal clustering of pathologies. Using the GERD score as a
continuous dependent criteria, several segmentation models were
studied with different sets of predictive variables. CHAID and
CR&T tree growing algorithms were used. Obtained stratum
proﬁles were further explored on non-signiﬁcant variables in the
search of multicolinearity and surrogates. RESULTS: A total of
3997 patients were recruited by 490 clinicians. Mean age was 49
(14.4) years and 48.4% were women. Reported comorbidities
were clustered in 6 antecedents and 15 concomitant pathologies.
Although hypertension was the most frequent comorbidity
(15.8%) only a small relation with other pathologies was found
(mainly with Diabetes, Dyslipemia, Osteoarthritis and Hypercho-
lesterolemia). The best stratiﬁcation predictor of mean GSFQ
score was the EQ-5D utility score. GERD severity, EQ-5D VAS
QoL, alcohol consumption, tabaquism, age, carbonic beverage
consumption depression and Ostheoartritis were also signiﬁcant
predictors at different tree levels. CONCLUSIONS: The Spanish
version of the GSFQ is sensitive to differences between patients
with respect to HRQoL, comorbidities and several risk factors.
Surprisingly, some risk factorswhich had no simple direct effect on
GSFQ scores were signiﬁcant in combination with other segmen-
tation criteria at lower tree levels.
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